CERO THERAPEUTICS INC has a total of 40 patent applications. It decreased the IP activity by 12.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets biotechnology, pharmaceuticals and foods and drinks are AUTOLUS LTD, CARSGEN THERAPEUTICS LTD and NANJING IASO BIOTHERAPEUTICS CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 7 | |
#2 | EPO (European Patent Office) | 6 | |
#3 | United States | 6 | |
#4 | Australia | 4 | |
#5 | Canada | 4 | |
#6 | China | 4 | |
#7 | Israel | 4 | |
#8 | Republic of Korea | 4 | |
#9 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Microorganisms | |
#4 | Therapeutic chemical compounds | |
#5 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Corey Daniel Mark | 35 |
#2 | Ibarra Ingrid | 7 |
#3 | Daniel Mark Corey | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021067875A1 | Chimeric tim4 receptors and uses thereof | |
US2021024607A1 | Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof | |
EP3774864A1 | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases | |
KR20210024443A | Cellular immunotherapy composition and use thereof | |
EP3774906A1 | Chimeric tim4 receptors and uses thereof | |
KR20200100598A | Chimeric phagocytosis receptor molecules and methods of use | |
CA3035080A1 | Chimeric engulfment receptor molecules |